As 2025 draws to a close, the "Magnificent Seven" era of market dominance is facing its most significant challenge yet. While the first half of the year was characterized by a relentless surge in mega-cap technology stocks, the final quarter of 2025 has seen a decisive shift in investor sentiment—
BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for the first-ever high-dose oral version of its blockbuster weight-loss treatment. The news, announced late yesterday on December 22, 2025, triggered
As 2025 draws to a close, the financial landscape has undergone a seismic shift that few predicted at the start of the year. For the first time in over half a decade, the dominant narrative of "Big Tech" exceptionalism is being challenged not by a market crash, but by a
The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally. Following the Federal Reserve’s third consecutive interest rate cut on December 10, 2025, institutional capital has begun a rapid
NEW YORK — In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index has finally staged its long-awaited breakout, signaling a definitive end to the years-long dominance of mega-cap technology. As of December 18, 2025, the index of small-cap stocks is stabilizing near the 2,
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated move, expected to be a 25-basis-point cut, is poised to reshape monetary policy landscapes, while persistent geopolitical tensions and the
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
